- Research collaboration with Eli Lilly on TPD with multiple targets.
- $10 million upfront, and a $10 million equity investment in Series A-2.
- Eligible to receive up to $780 million in potential milestones and tiered royalties of sales.
Our Partners
Eli Lilly
Eisai
- Series A-3 financing: first close of $24 million from investors led by Eisai in August 2024.
- SEED-Eisai Collaboration: SEED receive upfront and milestone payments of up to $1.5 billion plus tiered royalties upon Eisai’s exercise of their exclusive rights under the strategic research collaboration.
Partner with Us
We welcome partnership opportunities to leverage our proprietary RITE3™ TPD platform and R&D expertise in developing effective therapies and cures for patients.